Sheng Yang

发表

Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer.

Yuankai Shi, Y. Chi, Jian-liang Yang, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Aurora-A as an independent molecular prognostic marker in gastric cancer.

Yuankai Shi, Jing Wang, Sheng Yang, 2011, Oncology reports.

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer

Yuankai Shi, X. Hao, P. Hu, 2020, Journal of Hematology & Oncology.

Development and validation of a UPLC–MS/MS assay for the quantification of simotinib in human plasma

Yuankai Shi, Ning Li, Sheng Yang, 2014, Analytical and Bioanalytical Chemistry.

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients

P. Xing, Yuankai Shi, Dan Wang, 2020, Theranostics.

Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma

P. Liu, Yuankai Shi, Jian-liang Yang, 2013, Medical Oncology.

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Cancer management and research.

A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Asia-Pacific journal of clinical oncology.

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era

P. Liu, Yuankai Shi, Jian-liang Yang, 2016, Oncotarget.

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.

Peng Liu, Haifeng Song, Yuankai Shi, 2020, European journal of cancer.

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era

P. Liu, Jian-liang Yang, Sheng Yang, 2022, BMC cancer.

Dismal outcome of relapsed or primary refractory adult T‐cell lymphoblastic lymphoma: A retrospective study from China

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Asia-Pacific journal of clinical oncology.

Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Annals of Hematology.

Long‐term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single‐center retrospective study

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Asia-Pacific journal of clinical oncology.

Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type

P. Liu, P. Xing, Yuankai Shi, 2017, Annals of Hematology.

GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

P. Liu, Yuankai Shi, Ye-Xiong Li, 2016, Medicine.

吉非替尼治疗32例肺腺癌脑转移的临床经验

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Development and validation of an ultrafiltration-UPLC-MS/MS method for rapid quantification of unbound docetaxel in human plasma.

Yuankai Shi, Ning Li, Sheng Yang, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of total docetaxel from a lipid microsphere formulation in human plasma.

Yuankai Shi, Ning Li, Sheng Yang, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer].

Junling Li, Yuankai Shi, Yan Wang, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.

P. Liu, Yuankai Shi, Weihu Wang, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Chinese a Nti鄄 Cancer a Ssociation

P. Liu, Yuankai Shi, L. Xue, 2022 .

Absolute monocyte count is a prognostic indicator in a patient with diffuse large B-cell lymphoma after autologous peripheral blood stem cell transplant

Peng Liu, Yuankai Shi, Jian-liang Yang, 2015, Leukemia & lymphoma.

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges

H. Yao, Ying Cheng, Bing-he Xu, 2020, Cancer biology & medicine.

Low CCL19 Expression Is Associated With Adverse Clinical Outcomes For Patients With Advanced Stage Follicular Lymphoma

N. Lou, P. Liu, Yuankai Shi, 2021 .

CMAR_A_269624 11515..11522

P. Liu, Jian-liang Yang, Sheng Yang, 2020 .

The clinical features, treatment, and prognostic factors for peripheral T‐cell lymphomas: A single‐institution analysis of 240 Chinese patients

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Asia-Pacific journal of clinical oncology.

Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified

P. Liu, Yuankai Shi, Weihu Wang, 2017, Annals of Hematology.

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Sheng Yang, Yu-tao Liu, Lin Lin, 2022, Cancer Immunology, Immunotherapy.

Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases.

Jian-ping Xu, Xiaoyan Liu, Sheng Yang, 2020, Oncology research.

Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.

P. Liu, Shulian Wang, Ye-Xiong Li, 2018, International journal of radiation oncology, biology, physics.

Comparison of CBV, BEAM and BEAC high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non‐Hodgkin lymphoma: Efficacy and toxicity

P. Liu, Yuankai Shi, Jian-liang Yang, 2017, Asia-Pacific journal of clinical oncology.

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

P. Liu, Yuankai Shi, Jian-liang Yang, 2015, Chinese journal of cancer.

High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis

P. Liu, Yuankai Shi, Sheng Yang, 2013, International Journal of Hematology.

Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era

P. Liu, Shulian Wang, H. Fang, 2019, Leukemia & lymphoma.

Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018)

P. Liu, Yuankai Shi, H. Fang, 2022, Cancer Pathogenesis and Therapy.

Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Chronic diseases and translational medicine.

Efficacy and safety of the combination of paclitaxel and platinum in advanced thymic carcinoma

Yuankai Shi, X. Hao, Xiang-ru Zhang, 2015, Thoracic cancer.

A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections

P. Liu, Yuankai Shi, K. Sun, 2014, Anti-cancer drugs.

Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphoma.

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Future oncology.

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

T. Wang, Yanqiu Zhao, Jianying Zhou, 2023, BMC Medicine.

A new method of ultra‐performance liquid chromatography/tandem mass spectrometry for determination of chlorogenic acid in human plasma and urine

Yuankai Shi, Ning Li, Sheng Yang, 2020 .

Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas

P. Liu, P. Xing, Yuankai Shi, 2016, Hematology.

Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population

Yuankai Shi, Sheng Yang, Yan Sun, 2014, Translational oncology.

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma

D. Lin, Peng Liu, P. Xing, 2019, Front. Oncol..

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2016, OncoTargets and therapy.

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2016, Thoracic cancer.

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Sheng Yang, Yu-tao Liu, Lin Lin, 2022, Cancer Immunology, Immunotherapy.

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer

X. Yi, P. Liu, Y. Guan, 2019, Journal of cellular and molecular medicine.

Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.

P. Liu, Yuankai Shi, Jian-liang Yang, 2018 .

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2017, OncoTargets and therapy.

Efficacy of icotinib in lung squamous‐cell cancer: A real‐world experience from single institution

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2017, Asia-Pacific journal of clinical oncology.

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2019, Journal of Translational Medicine.

Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI

P. Xing, Yuankai Shi, Jun-ling Li, 2019, Journal of Cancer.

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial

Yuankai Shi, Ning Li, Sheng Yang, 2019, Cancer management and research.

191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析

P. He, Junling Li, Yuankai Shi, 2013, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[Evaluation of the role of rhIL-11 on hematological recovery in lymphoma patients after autologous hematopoietic stem cell transplantation].

P. Liu, Yuankai Shi, Jian-liang Yang, 2012, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis.

Guan-qing Wu, P. Liu, Yuankai Shi, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14‐year experience of a single‐center study

P. Liu, Yuankai Shi, Lingdi Zhao, 2012, Journal of clinical apheresis.

Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial

Junling Li, Yan Wang, Yalei Wang, 2018, Thoracic cancer.

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients

P. Xing, Jun-ling Li, Yan Wang, 2016, Cancer medicine.

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure

Yu Zhao, Yuankai Shi, Aichun Liu, 2018, Cancer science.

Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib

Peng Liu, Yuankai Shi, Biao Liu, 2020, Targeted Oncology.

Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Molecular Diagnosis & Therapy.

Chinese a Nti鄄 Cancer a Ssociation

Feng, P. Liu, P. Liu, 2022 .

Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy

N. Lou, P. Liu, Yuankai Shi, 2021, Journal of Translational Medicine.

Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma.

P. Liu, Yuankai Shi, Jian-liang Yang, 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens

P. Liu, Yuankai Shi, Jian-liang Yang, 2020, Journal of Cancer.

Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay.

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2021, Journal of pharmaceutical and biomedical analysis.

Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

P. Liu, Yuankai Shi, Sheng Yang, 2007, Chemotherapy.

The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era.

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Leukemia research.

Prognostic evaluation models for primary thyroid lymphoma, based on the SEER database and an external validation cohort

Sheng Yang, Yunshu Zhu, Xiaohui He, 2021, Journal of Endocrinological Investigation.

Molecular profiling of Chinese R‐CHOP treated DLBCL patients: Identifying a high‐risk subgroup

P. Liu, Yuankai Shi, Biao Liu, 2020, International journal of cancer.

[Prospective multicentre study of chemotherapeutic regimen containing pirarubicin on the treatment of relapsed or refractory acute myeloid leukemia in adults].

Hong-guo Zhao, Sheng Yang, M. Hou, 2014, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas

P. Liu, Yuankai Shi, Sheng Yang, 2015, Chinese medical journal.

A prognostic nomogram constructed for relapsed or refractory diffuse large B‐cell lymphoma patients

P. Liu, Yuankai Shi, Jian-liang Yang, 2019, Asia-Pacific journal of clinical oncology.

A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma

P. Liu, Yuankai Shi, Sheng Yang, 2019, Chinese medical journal.

Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era

P. Liu, Yuankai Shi, Jian-liang Yang, 2016, Chinese medical journal.

The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma.

Peng Liu, Yuankai Shi, Jian-liang Yang, 2014, Leukemia research.

MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma

P. Liu, T. Qiu, Jian-liang Yang, 2023, Journal of Cancer Research and Clinical Oncology.

Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis

P. Liu, Jian-liang Yang, Sheng Yang, 2015, Medical Oncology.

Clinical response to apatinib monotherapy in advanced non‐small cell lung cancer

Yuankai Shi, Xiaoyan Liu, Sheng Yang, 2018, Asia-Pacific journal of clinical oncology.

Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Leukemia & lymphoma.

A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.

Haifeng Song, Yuankai Shi, Jian-liang Yang, 2017 .

Suitability of Surgical Tumor

Yuankai Shi, Sheng Yang, Yan Sun, 2014 .

MiR-490-3p Inhibits the Malignant Progression of Lung Adenocarcinoma

Sheng Yang, Danfeng Jiang, Zhi-yang Li, 2020, Cancer management and research.

Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.

Yanqiu Zhao, Y. Shu, Gong-yan Chen, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China

P. Liu, P. Xing, Jian-liang Yang, 2019, BMJ Open.

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

Yuankai Shi, Jun Zhao, C. Bai, 2021, Journal of Clinical Oncology.

[Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].

Yang Zhang, Yunpeng Liu, Yuankai Shi, 2006, Zhonghua yi xue za zhi.

[Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].

Yuankai Shi, Sheng Yang, Yan Sun, 2006, Ai zheng = Aizheng = Chinese journal of cancer.

Efficacy and Safety of Gemcitabine-Based Combination Regimens in Patients with Extranodal Natural Killer/T Cell Lymphoma, Nasal Type

Yuankai Shi, L. Qiu, Weihu Wang, 2014 .

[Clinicopathological features and outcomes: analysis of 21 cases of lymphoma in pregnancy].

P. Liu, Yuankai Shi, P. Yuan, 2015, Zhonghua yi xue za zhi.

[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2005, Ai zheng = Aizheng = Chinese journal of cancer.

Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients

P. Liu, Jian-liang Yang, Sheng Yang, 2023, European journal of haematology.

A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2015, Leukemia & lymphoma.

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2019, Journal of Translational Medicine.

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure

Yu Zhao, Yuankai Shi, Aichun Liu, 2018, Cancer science.